EMORY UNIVERSITY HOSPITAL
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $363.1M
- Transactions
- 27,349
- Companies
- 40
- Average per transaction
- $13,275
Who reported the payments
| Pfizer | $49,445,182 |
| Gilead | $24,172,943 |
| Merck | $20,999,824 |
| Takeda Pharmaceuticals U.S.A., Inc. | $18,581,146 |
| E.r. Squibb & Sons, L.L.C. | $13,129,544 |
| Amgen | $12,899,947 |
| AstraZeneca | $12,651,321 |
| Bristol Myers Squibb | $11,259,901 |
| Novartis | $8,871,037 |
| Eli Lilly | $8,377,141 |
| Janssen Research & Development, LLC | $7,899,925 |
| AbbVie | $7,412,251 |
| Edwards Lifesciences | $7,337,799 |
| Medical Device Business Services, Inc. | $7,120,345 |
| Seagen Inc. | $6,618,873 |
| Genentech, Inc. | $6,254,715 |
| Medtronic | $5,804,075 |
| Abbott | $5,372,519 |
| Biomarin Pharmaceutical Inc. | $5,076,103 |
| Regeneron | $5,018,535 |
| Biogen | $4,705,258 |
| Boehringer Ingelheim | $4,589,082 |
| Ipsen Biopharmaceuticals, Inc | $3,805,925 |
| Roche Diagnostics Corporation | $3,690,874 |
| Sanofi | $3,685,957 |
| Vertex | $3,090,768 |
| Siemens Medical Solutions USA, Inc. | $2,980,106 |
| Boston Scientific | $2,976,873 |
| Daiichi Sankyo Inc. | $2,642,010 |
| Shire North American Group Inc | $2,589,653 |
| Eisai Inc. | $2,557,809 |
| Sanofi US Services Inc. | $2,525,305 |
| Incyte Corporation | $2,478,502 |
| Sanofi Pasteur Inc. | $2,373,793 |
| CSL Behring | $2,277,636 |
| Novo Nordisk | $2,150,309 |
| Stryker | $2,039,291 |
| Blue Earth Diagnostics | $1,922,665 |
| Exelixis Inc. | $1,895,083 |
| Tesaro, Inc. | $1,709,832 |